Danaher Corporation (DHR) has been benefiting from strength in its Diagnostics segment and accretive acquisitions. The company’s measures to reward its shareholders are encouraging.Let’s discuss the factors that should influence investors to retain this Zacks Rank #3 (Hold) company for the time being.Growth Catalysts of DHRBusiness Strength: Strength in Danaher’s clinical diagnostics business, driven by growth in Leica Biosystems and Beckman Colter Diagnostics units, has been supporting the Diagnostics segm ...